Securian Asset Management Inc. Cuts Position in Boston Scientific Corporation $BSX

Securian Asset Management Inc. lessened its holdings in Boston Scientific Corporation (NYSE:BSX) by 43.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 40,310 shares of the medical equipment provider’s stock after selling 31,250 shares during the quarter. Securian Asset Management Inc.’s holdings in Boston Scientific were worth $3,844,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BSX. Brighton Jones LLC boosted its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares during the last quarter. FWL Investment Management LLC purchased a new position in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. Main Street Financial Solutions LLC boosted its stake in shares of Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after buying an additional 1,971 shares during the last quarter. Ieq Capital LLC boosted its stake in shares of Boston Scientific by 97.0% in the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after buying an additional 60,860 shares during the last quarter. Finally, HUB Investment Partners LLC boosted its stake in shares of Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after buying an additional 2,556 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 0.1%

NYSE:BSX opened at $53.89 on Monday. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $80.08 billion, a PE ratio of 22.55, a price-to-earnings-growth ratio of 0.99 and a beta of 0.62. The firm’s 50 day moving average is $65.95 and its 200 day moving average is $83.68. Boston Scientific Corporation has a 12 month low of $53.63 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the previous year, the firm posted $0.75 EPS. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on BSX. Daiwa Securities Group downgraded Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Robert W. Baird lowered their price target on shares of Boston Scientific from $86.00 to $78.00 and set an “outperform” rating on the stock in a report on Thursday, April 23rd. Canaccord Genuity Group lowered their price target on shares of Boston Scientific from $109.00 to $71.00 and set a “buy” rating on the stock in a report on Thursday, April 23rd. Finally, JPMorgan Chase & Co. lowered their price target on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $93.91.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.